Form 4: Arcus Biosciences General Counsel, Carolyn C. Tang, Reports Changes in Beneficial Ownership

Carolyn C. Tang, General Counsel of Arcus Biosciences, reports the disposition of 4,182 shares of common stock to cover tax obligations related to RSU vesting, while also increasing holdings through an employee stock purchase plan.

Summary

• On June 15, 2024, Carolyn C. Tang, General Counsel of Arcus Biosciences, disposed of 4,182 shares of common stock to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The disposition was a 'net settlement' by Arcus Biosciences at a price of $16.97 per share.
• Following the transaction, Tang directly owns 111,364 shares of Arcus Biosciences common stock.
• This total includes 967 shares purchased on May 31, 2024, through the company's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine transactions related to executive compensation and stock ownership. The purchase of shares through the employee stock purchase plan is a slightly positive signal.

Positives

• Tang increased her holdings by 967 shares through the Employee Stock Purchase Plan, showing confidence in the company.
• The reporting person still holds a significant amount of shares after the transaction.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Stakeholder Impact

• Shareholders may view insider transactions as a signal of management's confidence (or lack thereof) in the company's future prospects.
• Employees participating in the stock purchase plan are directly impacted by the company's stock performance.

Key Dates